Mipomersen as a potential adjunctive therapy for hypercholesterolemia

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.15, 2010-10, pp. : 2569-2572

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Remacemide: potential as adjunctive therapy in PD

Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

By Vogt Anja Parhofer Klaus G

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 691-697

Informa Healthcare

Access to resources Recommend Favorite

Mipomersen

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. : 271-279

Adis International

Access to resources Recommend Favorite

Therapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia

By Gelsinger Carmen Steinhagen-Thiessen Elisabeth Kassner Ursula

Drugs, Vol. 72, Iss. 11, 2012-07 ,pp. : 1445-1455

Adis International

Access to resources Recommend Favorite

Gene Therapy for Familial Hypercholesterolemia

Current Pharmaceutical Design, Vol. 17, Iss. 24, 2011-08 ,pp. : 2575-2591

Bentham Science Publishers

Access to resources Recommend Favorite